文档下载 文档下载导航
设为首页 | 加入收藏
搜索 请输入内容:  
 导航当前位置: 文档下载 > 所有分类 > 医药卫生 > pk-pd modeling of drug-induced effect on the QT interval in conscious telemetered dogs
侵权投诉

pk-pd modeling of drug-induced effect on the QT interval in conscious telemetered dogs

药动/药效模型的具体应用

A.Ollerstametal./JournalofPharmacologicalandToxicologicalMethods53(2006)174–183183

Acknowledgements

WewouldliketothankJennySo¨derstro¨m,AnnicaHa¨gg,NinaAhlstro¨mandMalinAntonssonforskilledtechnicalassistanceandanimalprocedures.

References

Abel,S.,Nichols,D.J.,Brearley,C.J.,&Eve,M.D.(2000).Effectof

cimetidineandranitidineonpharmacokineticsandpharmacodynamicsofasingledoseofdofetilide.BritishJournalofClinicalPharmacology,49,64–71.

Allen,M.J.,Nichols,D.J.,&Oliver,S.D.(2000).Thepharmacokineticsand

pharmacodynamicsoforaldofetilideaftertwicedailyandthreetimesdailydosing.BritishJournalofClinicalPharmacology,50,247–253.

Allen,M.J.,Oliver,S.D.,Newgreen,M.W.,&Nichols,D.J.(2002).

PharmacodynamiceffectofcontinuousvsintermittentdosingofdofetilideonQTinterval.BritishJournalofClinicalPharmacology,53,59–65.

Barrett,J.F.(2000).Moxifloxacinbayer.CurrentOpinioninInvestiga-tionalDrugs,1,45–51.

Brown,A.M.(2004).Drugs,hERGandsuddendeath.CellCalcium,35,

543–547.

Can,I.,Aytemir,K.,Kose,S.,&Oto,A.(2002).Physiologicalmechanisms

influencingcardiacrepolarizationandQTinterval.CardiacElectro-physiologyReview,6,278–281.

Crumb,W.,&Cavero,I.(1999).QTintervalprolongationbynon-cardiovasculardrugs:Issuesandsolutionsfornoveldrugdevelopment.PharmaceuticalScienceandTechnologyToday,2,270–280.

DePonti,F.,Poluzzi,E.,Cavalli,A.,Recanatini,M.,&Montanaro,N.

(2002).Safetyofnon-antiarrhythmicdrugsthatprolongtheQTintervalorinducetorsadedepointes:Anoverview.DrugSafety,25,263–286.DePonti,F.,Poluzzi,E.,&Montanaro,N.(2001).Organisingevidenceon

QTprolongationandoccurrenceofTorsadesdePointeswithnon-antiarrhythmicdrugs:Acallforconsensus.EuropeanJournalofClinicalPharmacology,57,185–209.

El-Sherif,N.,&Turitto,G.(2003).Torsadedepointes.CurrentOpinionin

Cardiology,18,6–13.

Gwilt,M.,Blackburn,K.J.,Burges,R.A.,Higgins,A.J.,Milne,A.A.,&

Solca,A.M.(1992).Electropharmacologyofdofetilide,anewclassIIIagent,inanaesthetiseddogs.EuropeanJournalofPharmacology,215,137–144.

Hammond,T.G.,Carlsson,L.,Davis,A.S.,Lynch,W.G.,MacKenzie,

I.,Redfern,W.S.,etal.(2001).Methodsofcollectingandevaluatingnon-clinicalcardiacelectrophysiologydatainthepharmaceuticalindustry:Resultsofaninternationalsurvey.CardiovascularResearch,49,741–750.

Hanada,E.,Ohtani,H.,Kotaki,H.,Sawada,Y.,Sato,H.,&Iga,T.(1999).

Pharmacodynamicanalysisoftheelectrocardiographicinteractionbetweendisopyramideanderythromycininrats.JournalofPharma-ceuticalSciences,88,234–240.

Johansson,L.,Sohn,D.,Thorberg,S.-O.,Jackson,D.M.,Kelder,D.,Larsson,

L.-G.,etal.(1997).Thepharmacologicalcharacterizationofanovelselective5-hydroxytryptamine1Areceptorantagonist,NAD-299.JournalofPharmacologicalExperimentalTherapeutics,283,216–225.

Johnson,B.F.,Cheng,S.L.,&Venitz,J.(2001).Transientkineticand

dynamicinteractionsbetweenverapamilanddofetilide,aclassIIIantiarrhythmic.JournalofClinicalPharmacology,41,1248–1256.Kleinbloesem,C.H.,VanBrummelen,P.,Danhof,M.,Faber,H.,Urquhart,

J.,&Breimer,D.D.(1987).Rateofincreaseintheplasmaconcentrationofnifedipineasamajordeterminantofitshemodynamiceffectsinhumans.ClinicalPharmacology&Therapeutics,41,26–30.

LeCoz,F.,Funck-Brentano,C.,Morell,T.,Ghadanfar,M.M.,&Jaillon,

P.(1995).Pharmacokineticandpharmacodynamicmodelingoftheeffectsoforalandintravenousadministrationsofdofetilideonventricularrepolarization.ClinicalPharmacology&Therapeutics,57,533–542.

Malik,M.(2001).Problemsofheartratecorrectioninassessmentofdrug-inducedQTintervalprolongation.JournalofCardiovascularElectro-physiology,12,411–420.

Malik,M.,Farbom,P.,Batchvarov,V.,Hnatkova,K.,&Camm,A.J.

(2002).RelationbetweenQTandRRintervalsishighlyindividualamonghealthysubjects:ImplicationsforheartratecorrectionoftheQTinterval.Heart,87,220–228.

Minematsu,T.,Ohtani,H.,Sato,H.,&Iga,T.(1999).SustainedQT

prolongationinducedbytacrolimusinguineapigs.LifeSciences,65,PL197–PL202.

Minematsu,T.,Ohtani,H.,Yamada,Y.,Sawada,Y.,Sato,H.,&Iga,T.

(2001).QuantitativerelationshipbetweenmyocardialconcentrationoftacrolimusandQTprolongationinguineapigs:Pharmacokinetic/phar-macodynamicmodelincorporatingasiteofadverseeffect.JournalofPharmacokineticsandPharmacodynamics,28,533–554.

Ohtani,H.,Taninaka,C.,Hanada,E.,Kotaki,H.,Sato,H.,Sawada,Y.,etal.

(2000).ComparativepharmacodynamicanalysisofQ–Tintervalprolongationinducedbythemacrolidesclarithromycin,roxithromycin,andazithromycininrats.AntimicrobialAgentsandChemotherapy,44,2630–2637.

Rampe,D.,Murawsky,M.K.,Grau,J.,&Lewis,E.W.(1998).The

antipsychoticagentsertindoleisahighaffinityantagonistofthehumancardiacpotassiumchannelHERG.JournalofPharmacologyandExperimentalTherapeutics,286,788–793.

Rasmussen,H.S.,Allen,M.J.,Blackburn,K.J.,Butrous,G.S.,&

Dalrymple,H.W.(1992).Dofetilide,anovelclassIIIantiarrhyth-micagent.JournalofCardiovascularPharmacology,20(Suppl2),S96–S105.

Raunig,D.,Depasquale,M.J.,Huang,C.H.,Winslow,R.,&Fossa,A.A.

(2001).StatisticalanalysisofQTintervalasafunctionofchangesinRRintervalintheconsciousdog.JournalofPharmacologicalandToxicologicalMethods,46,1–11.

Redfern,W.S.,Carlsson,L.,Davis,A.S.,Lynch,W.G.,MacKenzie,I.,

Palethorpe,S.,etal.(2003).Relationshipsbetweenpreclinicalcardiacelectrophysiology,clinicalQTintervalprolongationandtorsadedepointesforabroadrangeofdrugs:Evidenceforaprovisionalsafetymarginindrugdevelopment.CardiovascularResearch,58,32–45.

Segre,G.(1968).Kineticsofinteractionbetweendrugsandbiological

systems.Farmaco.EdizioneScientifica,23,907–918.

Sheiner,L.B.,Stanski,D.R.,Vozeh,S.,Miller,R.D.,&Ham,J.(1979).

Simultaneousmodelingofpharmacokineticsandpharmacodynamics:applicationtod-tubocurarine.ClinicalPharmacology&Therapeutics,25,358–371.

Smith,D.A.,Rasmussen,H.S.,Stopher,D.A.,&Walker,D.K.(1992).

Pharmacokineticsandmetabolismofdofetilideinmouse,rat,dogandman.Xenobiotica,22,709–719.

Vanoli,E.,Priori,S.G.,Nakagawa,H.,Hirao,K.,Napolitano,C.,Diehl,L.,

etal.(1995).Sympatheticactivation,ventricularrepolarizationandIkrblockade:Implicationsfortheantifibrillatoryefficacyofpotassiumchannelblockingagents.JournaloftheAmericanCollegeofCardiol-ogy,25,1609–1614.

Walker,D.K.,Alabaster,C.T.,Congrave,G.S.,Hargreaves,M.B.,

Hyland,R.,Jones,B.C.,etal.(1996).Significanceofmetabolisminthedispositionandactionoftheantidysrhythmicdrug,dofetilide.Invitrostudiesandcorrelationwithinvivodata.DrugMetabolismandDisposition,24,447–455.

Wang,J.,DellaPenna,K.,Wang,H.,Karczewski,J.,Connolly,T.M.,

Koblan,K.S.,etal.(2003).FunctionalandpharmacologicalpropertiesofcanineERGpotassiumchannels.AmericanJournalofPhysiology.HeartandCirculatoryPhysiology,284,H256–H267.

上一页第10页

你可能喜欢

热门文档

相关文档

站点地图 | 文档上传 | 侵权投诉 | 手机版
本站所有资源均来自互联网,本站只负责收集和整理,均不承担任何法律责任,如有侵权等其它行为请联系我们.
文档下载 Copyright 2013 doc.guandang.net All Rights Reserved.  -  email